We have previously shown that BTZ induces genome-wide methylation changes in human neuroblastoma SH-SY5Y cells treated with this compound, and these changes are likely to play a significant role in the development of resistance to BTZ [13]. The gene discussed is CASC3; the disease is neuroblastoma.